INCY Announces New Late-Stage Data on Skin Disease Drug

Key Takeaways Incyte reported new 24-week interim STOP-HS data on povorcitinib in hidradenitis suppurativa.Nearly 60% of patients on both doses achieved HiSCR50, with pain relief seen from week 3 to week 24.Povrocitinib's safety profile remained consistent, with both doses well-tolerated across the trials.Incyte (INCY) announced new 24-week interim data from the STOP-HS program on pipeline candidate, povorcitinib (INCB54707), in adult patients with moderate to severe hidradenitis suppurativa (HS).The data w ...